Analyse from Yahoo board1. It’s only been 8 business days since the PR on Jan 31st indicating that the study (in terms of performance with regards to recruitment & testing) was completed. As indicates therein, the clinical data needs to be tabulated with final results submitted to FDA for EUA consideration. Remember that the clinics are not controlled by THRM (to avoid conflict of interest) so they are at mercy of an independent process, as managed by third parties reporting to FDA, to finalize this stage of the process. 8 business days is a very short period of time considering the forgoing. 2. In its prior PR update on Jan 20th with respect to status of Study, Management indicated that results to that point were “very promising”. My take on this is that the intervening delay due to Covid spike over holiday season allowed THRM to have a peek at a smaller sample of results that made it through that extended period (hence,the positive comment) but that subsequent patients were somewhat rushed through the process so as to complete the Study by end of January as promised by the CEO. It is obvious that with focus on completion, he did not want to comment further on further results that he had not even seen yet 3. Too many people on this forum suggesting that THRM is late to the game given Covid is over. This is furthest from the truth and candidly very comical considering that 40% of the world population are not vaccinated yet, which makes the world prone to other variants and subvariants (eg . Stealth Omicron). THRM is positioned perfectly to take advantage in North America and across the globe if approval can be obtained. 4. The sales from Acuvid will be immediately accretive to bottom line and cash flow as order flow will require material customer deposits etc to ensure continual supply to the likes of schools, large employers and all. This will be viewed as a boon from valuation perspective by the market 5. Too much trash talk about shorting, swing trading specialist, etc! Really? The average daily volume is 550k shares at best with over 205M shares floating in market. The volatility in the stock prices by mere pennies is being driving by macro market volatility and resulting weak hands who choose to fold their position. Personally, I applaud this weakness as it allows me to pick up more shares on the cheap.